Bosio Research Group

Immunity to Pulmonary Pathogens Section

The directive of the Immunity to Pulmonary Pathogens Section (IPPS) is to further our understanding of how virulent pulmonary pathogens, including Francisella tularensis, Bordetella pertussis and SARS-CoV-2 evade and inhibit protective immunity in the lung. Our overall goal is to utilize this information for development of novel therapeutics and vaccines directed against a variety of infectious diseases. Additionally, through comparative studies using other pulmonary pathogens we aim to gain a comprehensive understanding of regulation of innate and adaptive immune responses in the lungs with a special emphasis on metabolism.

Catharine (Katy) Bosio, Ph.D.

Chief, Immunity to Pulmonary Pathogens Section

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., 1998, Colorado State University

B.Sc., 1993, Washington State University

Dr. Bosio graduated from Washington State University cum laude with a B.Sc. in 1993, completed her Ph.D. at Colorado State University, and postdoctoral fellowships at the Food and Drug Administration Center for Biologics Evaluation and Research and at the U.S. Army Medical Research Institute for Infectious Diseases. She joined NIAID in 2007; her laboratory studies the host response to pulmonary pathogens.

Learn more about Catharine (Katy) Bosio, Ph.D.

Forrest Jessop, Ph.D.

Biologist

Contact: For contact information, search the NIH Enterprise Directory.

Dr. Jessop primary interest is understanding how metabolic flux influences innate responses in the lung. Dr. Jessop utilizes a variety of infection models and both in vitro and in vivo models and techniques to characterize changes in metabolism after infection. Dr. Jessop’s goal is to use this information to design novel therapeutics for a wide variety of diseases.

Learn more about Forrest Jessop, Ph.D.

Lydia M. Roberts, Ph.D.

Staff Scientist

Contact: For contact information, search the NIH Enterprise Directory.

Dr. Roberts primary interest in the development of T cell immunity in the lung. By using an array of comparative models Dr. Roberts is dissecting out the optimal metabolic milieu required to engender long lived T cell responses in the lung with the goal of development of improved vaccines.

Learn more about Lydia M. Roberts, Ph.D.